A 4Kscore cut-off of 7.5% for prostate biopsy decisions provides high sensitivity and negative predictive value for significant prostate cancer.

To evaluate the 4Kscore test’s low risk cut off of 7.5% as the indication to proceed with a prostate biopsy by combining data from two independent prospective multicentre trials in the United States which have validated the 4Kscore test as a continuous score to predict clinically significant prostate cancer.